The PennZone

~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced that their Phase 1 study evaluating DVX201, an allogeneic natural killer (NK) cell therapy, for the treatment of patients hospitalized with COVID-19 has been accepted for publication in Molecular Therapy Methods and Clinical Development.

The study, conducted by Coeptis Therapeutics, a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections. The results have been accepted for publication in Molecular Therapy Methods and Clinical Development.

According to the accepted manuscript, this is the first known study to demonstrate the safety of adoptive immunotherapy with allogeneic, off-the-shelf NK cells in patients with active COVID-19. This is particularly significant for high-risk patients who are at risk for disease progression.

DVX201 is an innovative NK cell therapy derived from pooled donor cord blood CD34+ cells. It is the first allogeneic NK cell adoptive immunotherapy used clinically that offers a scalable, consistent, and cost-effective solution to barriers in the allogeneic cell therapy space.

The study also reported no adverse events related to DVX201 infusions. This includes no cytokine release syndrome (CRS), which can be a serious complication of immunotherapy treatments. Additionally, observations from the study showed rapid improvements in oxygenation and pulmonary radiographic findings in patients who received DVX201 infusions. Some patients were even able to be discharged from the hospital within days of receiving the treatment.

More on The PennZone

• Color Card Administrator Highlights Growing Enterprise Demand for Operational Infrastructure in Business Card Identity Governance
• American Properties Celebrates Grand Opening and Ribbon Cutting Ceremony at Heritage at South
• MoMojo Records signs Arlen Roth; "Blues Grass" slated for August 7, 2026 release
• Crosswalk Ministries USA Announces 2026 Child and Family Well-Being Conference in Stockbridge, Georgia
• Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance

Dr. Joshua Hill, associate professor and physician at Fred Hutch Cancer Center and corresponding author of the study stated that despite advances in treatment and prevention strategies for SARS-CoV-2, COVID-19 still results in substantial morbidity in certain patient populations. This highlights the ongoing need for additional therapeutic options, especially among immune compromised individuals. While the study was not designed to assess efficacy, the findings demonstrate the safety and potential utility of NK cell therapy as a complementary therapeutic strategy for viral infections in high-risk patients.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed excitement about the positive results and looks forward to sharing the full findings in Molecular Therapy Methods and Clinical Development. He also mentioned that these results, along with their recently announced expanded license agreement with Deverra, further strengthens Coeptis' role in the fight against infectious diseases.

To access the full publication in Molecular Therapy Methods and Clinical Development, please visit: https://www.cell.com/molecular-therapy-family/m...

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their product portfolio includes assets licensed from Deverra Therapeutics such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage natural killer cell therapy technology. They are also developing a universal multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

More on The PennZone

• Filmmaker Preston A. Dent to Premiere "Harrisburg-The Movie" at Whitaker Center for the Arts
• Pollock Begg Family Law Attorneys Earn 2026 Pennsylvania Super Lawyers Honors at Every Level
• Research reveals "The Borderless Pay Standard," a 48-point gap between multinational employers and workers on transparent pay expectations
• Global.ai Appoints Freedomtech Solutions as Specialist Partner for Agentic AI
• Communities In Schools of Eastern Pennsylvania's Ready, Set, Graduate! Celebrates Over 100 Students in Two Ceremonies

Coeptis' business model is centered around maximizing the value of their current product portfolio through various agreements such as in-license agreements, out-license agreements, co-development relationships, and strategic partnerships to expand their product rights and offerings. They are particularly focused on targeting cancer and infectious diseases. The company is headquartered in Wexford, PA. For more information on Coeptis, please visit https://coeptistx.com/.

This article serves as a cautionary note regarding the potential of Coeptis' products and rights. Any forward-looking statements made in this article are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the success of clinical trials, regulatory approvals, and market acceptance of their products. Readers are advised to refer to the company's filings with the Securities and Exchange Commission for a more comprehensive understanding of these risks and uncertainties.

---

Show All News | Disclaimer | Report Violation